PharVision Advisers’s Clorox CLX Stock Holding History

PharVision Advisers’s Portfolio CLX Stock Details CLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,082	Closed	-$210K	–	210
2025 Q4	$210K	Buy	+2,082	New	+$226K	0.11%	516
2025 Q3	–	Sell	-4,249	Closed	-$510K	–	675
2025 Q2	$510K	Buy	+4,249	New	+$567K	0.73%	6

Other funds holding CLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PharVision Advisers's CLX Position: Q1 2026 in Review

PharVision Advisers sold out of Clorox (CLX) in Q1 2026, closing a stake of 2,082 shares — an estimated $210K sold.

PharVision Advisers first reported a position in CLX in Q2 2025 and held it in 2 quarters. The position peaked at $510K in Q2 2025. 1,080 funds tracked by Wall St. Rank hold CLX as of Q1 2026.

PharVision Advisers reported no remaining Clorox position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 2,082 Clorox shares in Q1 2026, an estimated $210K.
PharVision Advisers first reported a position in Clorox in Q2 2025 and held it in 2 quarters.
PharVision Advisers's Clorox position peaked at $510K in Q2 2025.
1,080 funds tracked by Wall St. Rank held Clorox as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.